Third-quarter 2017 results show the company's high-growth business model is not without risks.
News & Analysis: Teligent
These three healthcare stocks should be on ambitious investors' radars. Here's why.
Here's why Pfizer, Teligent, and Neurocrine Biosciences are all top pharmaceutical stocks to own this year.
Stocks are one of the best ways for individuals to build up wealth. Here are three stocks that could help you do it.
A team of contributors shares their picks for underappreciated pharmas that deserve more attention.
It's been a great half-decade to be an investor in these three stocks.
Low priced stocks with good growth prospects aren't easy to find, but they do exist.
Here's the case for, and against, buying Teligent's stock.
These three value stocks may be down, but they're far from out.
Shares tumbled despite the company reporting two positive developments during the month.